Response to a change in the AFT used in patients who had progression of the IA after transplantation
. | No. patients treated as salvage AFT* . | No. patients who responded to salvage AFT (%) . |
|---|---|---|
| Salvage AFT given for IA after allo-HSCT | ||
| Azoles (itraconazole/voriconazole) | 12 (8/4) | 3 (25) |
| AmB formulations (c-AmB/ABLC/L-AmB) | 9 (2/3/4) | 3 (33) |
| Caspofungin | 4 | 2 (50) |
| No salvage AFT | 10 | 1 (10)† |
| All patients at risk | 27‡ | 6 (22) |
. | No. patients treated as salvage AFT* . | No. patients who responded to salvage AFT (%) . |
|---|---|---|
| Salvage AFT given for IA after allo-HSCT | ||
| Azoles (itraconazole/voriconazole) | 12 (8/4) | 3 (25) |
| AmB formulations (c-AmB/ABLC/L-AmB) | 9 (2/3/4) | 3 (33) |
| Caspofungin | 4 | 2 (50) |
| No salvage AFT | 10 | 1 (10)† |
| All patients at risk | 27‡ | 6 (22) |
AmB indicates amphotericin B; and ABLC, AmB lipid complex.
Salvage antifungal therapy used after progression of IA after HSCT.
One patient was not given salvage AFT for progression of IA because his leukemia recurred shortly thereafter. Nevertheless, IA decreased more than 50% within 3 weeks.
In 8 (30%) of 27 patients, more than 1 drug was used in combination.